原发性干燥综合征肾脏病变:95例活检证实的多中心研究
这项法国全国性回顾性多中心研究纳入95例符合AECG或扩大AECG标准且经肾活检证实肾脏受累的原发性干燥综合征患者,中位年龄49岁。抗SSA/SSB抗体在TIN患者中常见且与更差肾脏预后相关。85.3%患者接受治疗(98.8%用糖皮质激素),诊断后12个月内eGFR显著改善(49.9 vs 39.8 ml/min/1.73 m²,P<0.001),但未发现免疫抑制剂优于单用激素的证据。
要点
- pSS肾脏受累以TIN为主(97.9%),常伴显著浆细胞浸润。
- 抗SSA和抗SSB抗体在TIN患者中常见,且与更差肾脏预后相关。
- 糖皮质激素治疗可改善eGFR,但免疫抑制剂未显示优于单用激素。
核心结论
- pSS肾脏受累多由TIN引起,伴显著T、B尤其浆细胞浸润,肾功能障碍通常孤立但可严重。
- 糖皮质激素可改善eGFR,但免疫抑制剂未显示优于单用激素,最佳治疗策略尚需进一步研究。
研究设计与样本
- 法国全国性、回顾性、多中心研究,纳入符合AECG或扩大AECG标准且经肾活检证实肾脏受累的pSS患者95例,中位年龄49岁。
主要发现
- 82/95例(86.3%)eGFR<60 ml/min;肾活检示TIN 93例(97.9%),浆细胞浸润频繁(75%)。
- 肾小球病变22例(23.2%),主要与冷球蛋白相关。
- TIN患者中抗SSA抗体76.8%、抗SSB抗体53.8%,且与更差肾脏预后相关。
- 诊断后12个月内eGFR显著改善(最终49.9 vs 基线39.8 ml/min/1.73 m²,P<0.001),尽管初始活检示明显间质纤维化。
关键数值与推荐
- eGFR<60 ml/min见于82/95例(86.3%)。
- TIN占93/95例(97.9%),浆细胞浸润占75%,肾小球病变占22/95例(23.2%)。
- 抗SSA抗体阳性76.8%,抗SSB抗体阳性53.8%。
- 12个月eGFR 49.9 vs 基线39.8 ml/min/1.73 m²,P<0.001。
临床怎么用
- 对pSS患者出现肾功能障碍应警惕TIN,肾活检有助于明确病理类型。
- 糖皮质激素可用于改善eGFR,但免疫抑制剂联合治疗的获益尚未证实。
- 抗SSA/SSB抗体阳性TIN患者可能肾脏预后更差,需密切监测。
局限性
- 回顾性设计,治疗获益比较可能存在混杂。
- 免疫抑制剂使用例数较少(21例),未证实优于单用激素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE.: Renal involvement is a rare event during primary SS (pSS). We aimed to describe the clinico-biological and histopathological characteristics of pSS-related nephropathy and its response to treatment. METHODS.: We conducted a French nationwide, retrospective, multicentre study including pSS patients fulfilling American-European Consensus Group criteria or enlarged American-European Consensus Group criteria, and with biopsy-proven renal involvement. RESULTS.: A total of 95 patients were included (median age 49 years). An estimated glomerular filtration rate (eGFR) of <60 ml/min was found in 82/95 patients (86.3%). Renal biopsy demonstrated tubulointerstitial nephritis (TIN) in 93 patients (97.9%), and frequent (75%) plasma cell infiltrates. Glomerular lesions were found in 22 patients (23.2%), mainly related to cryoglobulin. The presence of anti-SSA (76.8%) and anti-SSB (53.8%) antibodies was particularly frequent among patients with TIN and was associated with a worse renal prognosis. Eighty-one patients (85.3%) were treated, with CSs in 80 (98.8%) and immunosuppressive agents (mostly rituximab) in 21 cases (25.9%). Despite marked interstitial fibrosis at initial biopsy, kidney function improved significantly during the 12-month period following diagnosis (final eGFR 49.9 vs 39.8 ml/min/1.73 m 2 at baseline, P < 0.001). No proven benefit of immunosuppressive agents over steroid therapy alone was found in this study. CONCLUSION.: Renal involvement of pSS is mostly due to TIN with marked T, B and especially plasma cell infiltration. Renal dysfunction is usually isolated but can be severe. Use of CSs can improve the eGFR, but further studies are needed to define the best therapeutic strategy in this disease.
引用
- Jasiek M, Karras A, Le Guern V, et al. A multicentre study of 95 biopsy-proven cases of renal disease in primary Sjögren's syndrome. Rheumatology (Oxford). 2017. PMID: 27940588. doi:10.1093/rheumatology/kew376
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。